Trials / Completed
CompletedNCT03375632
Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)
Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemic Outpatients With or Without Gout
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Mochida Pharmaceutical Company, Ltd. · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for 14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male hyperuricemic outpatients with or without gout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FYU-981 | Oral daily dosing for 14 weeks |
Timeline
- Start date
- 2018-01-04
- Primary completion
- 2018-05-29
- Completion
- 2018-06-05
- First posted
- 2017-12-18
- Last updated
- 2018-09-24
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03375632. Inclusion in this directory is not an endorsement.